ANIP Quote, Financials, Valuation and Earnings

Allogene Therapeutics has a net margin of -16.29% compared to ANI Pharmaceuticals's net margin of -295454.55%. ANI Pharmaceuticals's return on equity of -1.54% beat Allogene Therapeutics's return on equity of -52.73%.

ANI Pharmaceuticals has a consensus price target of $78.67, signalling upside risk potential of 34.57%. On the other hand Allogene Therapeutics has an analysts' consensus of $9.23 which suggests that it could grow by 406.99%. Given that Allogene Therapeutics has higher upside potential than ANI Pharmaceuticals, analysts believe Allogene Therapeutics is more attractive than ANI Pharmaceuticals.

ANI Pharmaceuticals has a beta of 0.733, which suggesting that the stock is 26.67% less volatile than S&P 500. In comparison Allogene Therapeutics has a beta of 0.855, suggesting its less volatile than the S&P 500 by 14.457%.

ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Allogene Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals pays 8.65% of its earnings as a dividend. Allogene Therapeutics pays out -- of its earnings as a dividend. ANI Pharmaceuticals's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ANI Pharmaceuticals quarterly revenues are $148.3M, which are larger than Allogene Therapeutics quarterly revenues of $22K. ANI Pharmaceuticals's net income of -$24.2M is higher than Allogene Therapeutics's net income of -$66.3M. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 55.43x while Allogene Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 2.04x versus 3,853.42x for Allogene Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Armata Pharmaceuticals has a net margin of -16.29% compared to ANI Pharmaceuticals's net margin of --. ANI Pharmaceuticals's return on equity of -1.54% beat Armata Pharmaceuticals's return on equity of --.

ANI Pharmaceuticals has a consensus price target of $78.67, signalling upside risk potential of 34.57%. On the other hand Armata Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 239.81%. Given that Armata Pharmaceuticals has higher upside potential than ANI Pharmaceuticals, analysts believe Armata Pharmaceuticals is more attractive than ANI Pharmaceuticals.

ANI Pharmaceuticals has a beta of 0.733, which suggesting that the stock is 26.67% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.851, suggesting its less volatile than the S&P 500 by 14.895%.

ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals pays 8.65% of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend. ANI Pharmaceuticals's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ANI Pharmaceuticals quarterly revenues are $148.3M, which are larger than Armata Pharmaceuticals quarterly revenues of --. ANI Pharmaceuticals's net income of -$24.2M is lower than Armata Pharmaceuticals's net income of -$5.5M. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 55.43x while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 2.04x versus 746.32x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -16.29% compared to ANI Pharmaceuticals's net margin of 18.02%. ANI Pharmaceuticals's return on equity of -1.54% beat Protalix BioTherapeutics's return on equity of -29.54%.

ANI Pharmaceuticals has a consensus price target of $78.67, signalling upside risk potential of 34.57%. On the other hand Protalix BioTherapeutics has an analysts' consensus of -- which suggests that it could grow by 530.63%. Given that Protalix BioTherapeutics has higher upside potential than ANI Pharmaceuticals, analysts believe Protalix BioTherapeutics is more attractive than ANI Pharmaceuticals.

ANI Pharmaceuticals has a beta of 0.733, which suggesting that the stock is 26.67% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.711, suggesting its less volatile than the S&P 500 by 28.881%.

ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals pays 8.65% of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend. ANI Pharmaceuticals's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ANI Pharmaceuticals quarterly revenues are $148.3M, which are larger than Protalix BioTherapeutics quarterly revenues of $18M. ANI Pharmaceuticals's net income of -$24.2M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 55.43x while Protalix BioTherapeutics's PE ratio is 121.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 2.04x versus 3.82x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Viemed Healthcare has a net margin of -16.29% compared to ANI Pharmaceuticals's net margin of 6.69%. ANI Pharmaceuticals's return on equity of -1.54% beat Viemed Healthcare's return on equity of 8.88%.

ANI Pharmaceuticals has a consensus price target of $78.67, signalling upside risk potential of 34.57%. On the other hand Viemed Healthcare has an analysts' consensus of -- which suggests that it could grow by 57.46%. Given that Viemed Healthcare has higher upside potential than ANI Pharmaceuticals, analysts believe Viemed Healthcare is more attractive than ANI Pharmaceuticals.

ANI Pharmaceuticals has a beta of 0.733, which suggesting that the stock is 26.67% less volatile than S&P 500. In comparison Viemed Healthcare has a beta of 1.468, suggesting its more volatile than the S&P 500 by 46.781%.

ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viemed Healthcare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals pays 8.65% of its earnings as a dividend. Viemed Healthcare pays out -- of its earnings as a dividend. ANI Pharmaceuticals's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ANI Pharmaceuticals quarterly revenues are $148.3M, which are larger than Viemed Healthcare quarterly revenues of $58M. ANI Pharmaceuticals's net income of -$24.2M is lower than Viemed Healthcare's net income of $3.9M. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 55.43x while Viemed Healthcare's PE ratio is 31.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 2.04x versus 1.54x for Viemed Healthcare. Usually stocks with elevated PS ratios are considered overvalued.